| During the past decade, genome-wide association studies (GWAS) have successfully identified tens of thousands of genetic variants associated with complex traits and diseases. These studies have produced vast repositories of genetic variation and trait measurements across millions of individuals, providing tremendous opportunities for further analyses. However, privacy concerns and other logistical considerations often limit access to individual-level genetic data, motivating the development of methods that analyze summary association statistics. Here we review recent progress on statistical methods that leverage summary association data to gain insights into the genetic basis of complex traits and diseases.
Introduction
Genome-wide association studies (GWAS) have been broadly successful in identifying genetic variants associated to complex traits and diseases, explaining a significant fraction of narrow-sense heritability and occasionally pinpointing biological mechanisms 1 . These studies have produced vast databases of genetic variation (typically at the level of common single nucleotide polymorphisms (SNPs) included on genotyping arrays) in millions of individuals across hundreds of complex traits.
Further analyses of this data can yield important insights into the genetics of complex traits, but privacy concerns and other logistical considerations often restrict access to individual-level data. On the other hand, summary association statistics, defined here as per-allele SNP effect sizes (log odds ratios for case-control traits) together with their standard errors, are often readily available and can be used to compute z-scores (per-allele effect sizes divided by their standard errors; see Figure 1 ); we note that in some applications, allele frequencies may also be required. A partial list of publicly available summary association statistics from large GWAS is provided in Table 1 . Summary statistics also offer advantages in computational cost, which does not scale with the number of individuals in the study. These advantages have motivated the recent development of many new methods for analyzing summary association data, often in conjunction with linkage disequilibrium (LD) information from a population reference panel such as 1000 Genomes 2 .
Here, we review these summary statistic-based methods. First, we review methods for performing single-variant association tests, including meta-analysis, conditional association and imputation using summary statistics. Second, we review methods for performing gene-based association tests by incorporating transcriptome reference data or aggregating signals across multiple rare variants.
Third, we review methods for fine-mapping causal variants, including integration of functional annotation and/or trans-ethnic data. Fourth, we review methods for constructing polygenic predictions of disease risk and inferring polygenic architectures. Finally, we review methods for jointly analyzing multiple traits. We conclude with a discussion of research areas where further work on summary statistic based methods is needed.
Single-variant association tests
Meta-analysis using fixed-effects or random-effects models. Large consortia often combine multiple GWAS studies into a single aggregate analysis to boost power for discovering SNP associations of small effect. Studies are combined either by jointly analyzing summary association results from each study (meta-analysis) or by re-analyzing individual-level data across all studies (mega-analysis) 3 . It has been shown that meta-analysis attains similar power for association as mega-analysis, with fewer privacy constraints and logistical challenges (since only summary association data is shared across studies) 4 . Meta-analysis is usually performed using fixed-effects approaches, which assume that true effect sizes are the same across studies. If true effect sizes are expected to differ across studies, this heterogeneity can be explicitly modeled using random-effects methods, which include an extra variance term in the model to account for heterogeneity.
Traditional random-effects methods allow for heterogeneity under the null model, leading to low power even when heterogeneity is present. This motivated the development of a random-effects method based on a null model of no-heterogeneity, which increases power over traditional randomeffects methods 5 . Under this framework, a statistical test against a null model of no-heterogeneity can be viewed as a summation of a fixed-effect component and a heterogeneity component, thus connecting fixed-effects and random-effects meta-analysis 5 . Subsequent work has introduced the concept of posterior probability for each study to have a non-zero effect, aiding interpretation and power when only a subset of studies have non-zero effect 6 .
Conditional association using LD reference data. Conditional association, in which the association between SNP and trait is evaluated after conditioning on the top SNP at a locus, can be used to identify multiple signals of association at a previously identified GWAS locus. Conditional association methods have traditionally required individual-level data in order to jointly fit multiple SNPs. Recent work has shown that conditional and joint association analysis of multiple SNPs can be approximated using only summary association statistics together with linkage disequilibrium (LD) information estimated from a population reference panel such as 1000 Genomes (see Box 1) 7 .
This has enabled the discovery of new secondary associations at known loci for height, BMI, and other complex traits and diseases, increasing the variance explained by GWAS associations for these traits [8] [9] [10] ; for example, in a recent height GWAS, approximate conditional analysis using summary data identified 697 genome-wide significant SNPs, including 34 SNPs with r 2 >0.1 to a more significant SNP at the same locus 8 .
Imputation using summary association statistics.
A standard approach to boost association power in GWAS is to leverage LD information from a population reference panel to impute genotypes at variants not typed in the study 11 . Imputation is traditionally performed using individual-level data, which requires substantial computational resources and can be logistically cumbersome when new reference panels become available, particularly for large consortia combining data from multiple studies. As an alternative to imputation using individual-level data, approaches have been developed to perform imputation directly at the level of summary statistics [12] [13] [14] [15] [16] [17] [18] . The key insight of these approaches is that LD induces correlations between z-scores, which can be modeled using a multivariate normal (MVN) distribution with variance equal to the LD correlation matrix 19 . Thus, zscores at untyped SNPs can be imputed from observations at typed SNPs using conditional means and variances of the MVN distribution. Imputation using summary statistics recovers >80% of the information from imputation using individual-level data at common variants [14] [15] [16] , and is practical and efficient since the imputed summary statistics are linear combinations of the observed statistics (see Box 1) . However, imputation using summary statistics cannot capture non-linear relationships between SNPs, which are modeled using haplotypes in imputation from individual-level data.
Conditional association and imputation using summary statistics critically rely on accurate LD information from a population reference panel. Even in the best case where the reference population closely matches the GWAS population, the relatively small reference panel size (typically hundreds or at most thousands of individuals) makes accurate estimation of a large number of LD parameters a challenge. This motivates regularization of the estimated LD matrix, both to maximize accuracy and to ensure robustness in the case of imputation using summary statistics, as mis-estimation of the variance of imputed statistics can lead to false-positive associations. A simple approach to regularization is to set all correlations between distal SNPs to zero, based on a fixed distance threshold 7 or approximately independent LD blocks inferred from the data 20 . An alternative is to specify a prior distribution and compute Bayesian posteriors 12 ; data can be combined across multiple ancestry reference panels to further boost accuracy 17, 18 . Singular value decomposition based approaches have also been proposed in other contexts 10 . In general, the accuracy of conditional association and imputation using summary statistics is reduced at low-frequency variants and when the LD structure between typed and imputed SNPs is mis-specified (e.g., when the ancestry of the GWAS sample does not exactly match the reference panel). We note that concerns about falsepositive associations in imputation using summary statistics can be avoided entirely via the release of in-sample summary LD information, i.e. pairwise correlations between all typed SNPs.
Gene-based association tests
Gene-based association using transcriptome reference data. GWAS risk variants are significantly enriched for genetic variants that impact gene expression (eQTLs) 21 . This motivates the paradigm of transcriptome-wide association studies (TWAS), which evaluate the association between the expression of each gene and a complex trait of interest. Due to the limited availability of very large samples with measured gene expression and trait values, initial TWAS approaches integrated eQTL and GWAS to identify susceptibility genes either via matching the association signals [22] [23] [24] , via mediation analyses 25 , or via assessing whether the same causal variant impacts both gene expression and trait under a single causal variant model [26] [27] [28] .
More recent studies have leveraged predicted expression to improve the power of TWAS. Under this paradigm, transcriptome reference data is used to predict gene expression in the GWAS data set (using cis SNPs, e.g. within 1Mb of the transcription start site), followed by a test for association between predicted expression and trait. Although originally proposed using individual-level data 29 , TWAS using predicted expression can also be performed using only summary association statistics and summary LD information 30, 31 . The key intuition is that the correlation between a weighted linear combination of SNPs (i.e. predicted gene expression) and trait is equivalent to a weighted linear combination of correlations between SNPs and trait (i.e. summary association statistics from GWAS) (see Figure 2 ). Since TWAS using predicted expression is conceptually similar to a test for non-zero genetic covariance between gene expression and trait 30 , it can also be performed via a twosample Mendelian randomization from summary statistics 31 . TWAS using predicted expression can increase power over a standard GWAS when there exist multiple causal variants whose effect on trait is mediated through expression. TWAS also reduces the multiple hypothesis burden by testing tens of thousands of genes instead of millions of SNPs. TWAS using predicted expression typically uses individual-level transcriptome reference data to predict gene expression, but can also be performed using only summary association statistics between SNPs and gene expression, albeit with a reduction in power 30 . The potential power gains of TWAS are underscored by the recent identification of 71 new susceptibility genes across 28 complex traits, of which 17 have no GWAS association within 1 Mb 32 . However, TWAS is underpowered compared to standard GWAS when the true biological mechanism is independent of gene expression or when expression data in the most relevant tissue is not available.
Rare variant association tests.
Although most GWAS of complex traits and diseases have focused on common variants that are typed on genotyping arrays or imputed from population reference panels, rare variant associations may also provide a rich source of biological insights, particularly for traits under strong negative selection 33, 34 . Because association tests of individual rare variants are likely to be underpowered, rare variant association tests generally aggregate evidence for association across multiple rare variants at a locus. In exome sequencing studies (or exome array studies), rare variants are aggregated at the gene level, making the gene the unit of association. This can be done either using burden tests, which assume that all rare variants in a candidate gene have the same direction of effect, or using overdispersion tests, which assume that rare variants in a candidate gene can impact a complex trait in either direction; hybrid omnibus tests are also possible 35 . Recent studies have shown that both burden tests and overdispersion tests can be performed using only summary association statistics from each rare variant, together with summary LD information [36] [37] [38] (see Box 2). Roughly, burden tests are computed as weighted sums of single-variant z-scores and overdispersion tests are computed as weighted sums of squared single-variant z-scores (analogous to previous work on common variant overdispersion tests using summary statistics 39 ), with summary LD information used to specify appropriate null distributions in each case. However, a key limitation is that these studies require the use of in-sample summary LD information in preference to reference LD information to ensure appropriate null distributions and avoid false-positive associations. Thus, in contrast to summary statistic based methods for common variants (see above), both summary association statistics and in-sample summary LD information are required in order for these methods to be useful (see Discussion). An additional limitation is that, for casecontrol traits, asymptotic null distributions may not be valid when variant counts or case or control sample sizes are small, necessitating careful scrutiny of quantile-quantile plots.
Fine-mapping
Fine-mapping using posterior probabilities of causality. Statistical fine-mapping aims to identify the causal variant(s) that are driving a GWAS association signal, enabling functional experiments to validate biological function. A straightforward approach to fine-mapping is to prioritize variants based on the strength of the marginal association statistics (i.e. ranking p-values) 40 . This is an effective strategy in the case of a single causal variant, but can be suboptimal when multiple causal variants are present, as the SNP with the top p-value at the locus may be tagging multiple causal
variants. An alternative is to compute the posterior probabilities of causality for every SNP in the region, based on the likelihoods of the observed z-scores conditional on each possible set of causal variant(s) 41 . These posterior probabilities can be used to construct a credible set of SNPs, defined as the smallest set of SNPs that contains the true causal variant(s) with a given probability (typically 90% or 99%). Initial studies approximated the posterior probabilities of causality under a single causal variant assumption. Under this assumption, posterior probabilities of causality can be estimated from z-scores without the need for LD information 42 ; this approach is both practical and computationally efficient. More recent studies have computed posterior probabilities of causality under a multiple causal variant assumption 43 . As in the case of imputation using summary statistics, the likelihoods of the observed z-scores can be computed based on the multi-variate normal (MVN) distribution with variance equal to the LD correlation matrix, with LD estimated from population reference panels using regularization techniques. Unlike imputation using summary statistics, which uses the null model of no association (i.e. a mean of 0 in the MVN), in fine-mapping the mean is a function of causal effect sizes, which can be heuristically approximated or integrated out using conjugate priors 43, 44 . These methods often restrict computations to a maximum number of causal variants (e.g. 3 or 6); more recent studies have shown that further speed-ups can be achieved through matrix factorizations 45 or stochastic search 46 . Methods that model multiple causal variants generally improve the accuracy (and calibration) of credible sets at loci with multiple causal variants [43] [44] [45] [46] [47] , with very limited decreases in accuracy at loci with only a single causal variant [43] [44] [45] [46] [47] [48] [49] . A less accurate alternative is to use conditional association analysis to detect multiple signals of associations 7,50,51 , followed by estimation of posterior probabilities of causality under a single causal variant assumption for each independent signal. In this case, special care is required in specifying the boundaries of each independent signal and the threshold for the conditional test.
Leveraging functional annotation data. Fine-mapping accuracy can be improved by integrating functional annotation data such as predicted regulatory elements from the ENCODE and ROADMAP Epigenomics projects 52, 53 . This approach is motivated by early studies showing that disease-associated variants are systematically enriched in chromatin marks that delineate active regulatory regions in disease-relevant cell types 54, 55 . Under this paradigm, a statistical model is developed to jointly estimate functional enrichment and update posterior probabilities of causality using functional annotations 44, 49, 56, 57 . Some integrative methods assume that SNPs are unlinked 57 or assume a single causal variant per locus 49, 56 , but a recent study built upon the multiple causal variant model of ref. 43 to incorporate functional annotation data 44 . In an analysis of rheumatoid arthritis summary association data, integrative fine-mapping using this approach reduced the average size of 90% credible sets by 10% 58 . In addition to increasing fine-mapping accuracy, these studies have also provided insights into polygenic architectures (see below) by identifying tissue-specific functional annotations that are enriched for causal disease signals. This can also be achieved by conducting fine-mapping without integrating functional annotation data (typically under a single causal variant assumption) and then overlapping the resulting credible sets with functional annotation data to assess enrichment [59] [60] [61] . Future integrative methods could increase fine-mapping resolution by integrating probabilistic functional annotations (e.g., ChIP-seq peak intensity) or modeling the strength of association between SNPs and chromatin marks in population-based studies 62, 63 .
Trans-ethnic fine-mapping.
Fine-mapping accuracy can also be improved by leveraging differences in LD patterns across continental populations that have arisen due to differences in demographic events such as population bottlenecks (see Figure 3 ) [64] [65] [66] [67] . Intuitively, the set of tag SNPs linked to a causal variant will vary across populations, so that aggregating evidence of association across populations will dilute signals from tag SNPs and strengthen signals from causal variants. A standard approach to combining information across multiple studies is to compute posterior probabilities of causality from fixed-effects meta-analysis results 64, 66, 68, 69 . Alternately, posterior probabilities can be computed from results of random-effects trans-ethnic meta-analysis methods 61, 65 . These approaches assume a single causal variant and thus do not require LD information from the underlying populations. More recent studies have introduced hierarchical probabilistic models that allow for multiple causal variants while incorporating LD information from population reference panels 58 . These studies assume that causal variants are shared across populations but allow for heterogeneity in effect sizes across populations, and can also incorporate functional annotation data to further increase fine-mapping accuracy 58 . In an analysis of rheumatoid arthritis summary association data in Europeans and Asians (see above), trans-ethnic fine-mapping reduced the average size of 90% credible sets by 25%, and by 32% when also integrating functional annotation data 58 .
Polygenicity of complex traits
Polygenic risk prediction. Although the main focus of complex disease genetics is to gain insights about disease biology, genetics can also be leveraged to build predictions of disease risk, which may become clinically useful as sample sizes increase 70, 71 . A landmark study of schizophrenia showed that polygenic risk scores, constructed by summing the predicted effects of all markers below a Pvalue threshold in the training sample, produced predictions of schizophrenia risk in validation samples that were significantly better than random, and far more accurate than those based on the single genome-wide significant locus identified in the study 72 . This provided an early demonstration of the advantages of incorporating markers that do not attain genome-wide significance into polygenic risk scores to improve prediction accuracy for polygenic traits. One complexity of polygenic risk scores is that of LD between markers, which has historically been addressed by LDpruning-either without regard to P-values 72 , or via informed LD-pruning 73 (clumping) that preferentially retains markers with more significant P-values. More recent work has shown that explicitly modeling LD using an LD reference panel and estimating posterior mean causal effect sizes can improve prediction accuracy from summary statistics 74 . An alternative to summary statistic based methods is to fit effect sizes of all markers simultaneously using Best Linear Unbiased Prediction (BLUP) methods and their extensions [75] [76] [77] , which require individual-level training data. Fitting all markers simultaneously is theoretically more appropriate and can produce more accurate predictions, although the relative advantage is small when overall prediction accuracies are modest (Box 3). In their simplest form, polygenic risk scores and BLUP methods assume infinitesimal (Gaussian) architectures in which all markers are causal, but these methods have been extended to increase prediction accuracy in the case of non-infinitesimal architectures; this has been accomplished for polygenic risk scores via restricting to markers below a P-value threshold 72 or estimating posterior mean causal effect sizes under a point-normal prior 74 , and for BLUP methods by estimating (joint-fit) posterior mean causal effect sizes under a normal mixture prior 78, 79 . Although polygenic risk scores must await even larger training sample sizes to attain clinical utility, appreciable prediction accuracies have been achieved for some traits, including a Nagelkerke R 2 of 0.25 (AUC: 75%) for schizophrenia 74 . An important caveat is that it is critical when constructing and evaluating polygenic risk scores to avoid non-independence of training and validation samples (e.g. due to cryptic relatedness or shared population stratification), which could cause prediction accuracy to be overstated relative to what could be achieved in an independent validation sample 74, 80 .
Inferring polygenic architectures.
It is increasingly clear that most complex traits and diseases have highly polygenic architectures, with a large number of causal variants of small effect. In order to understand these polygenic architectures, it is of interest to infer parameters such as the heritability explained by SNPs and the number of causal variants. Both of these quantities have been estimated using accuracies of polygenic risk scores (see above), as a function of the P-value threshold used to constrain the set of markers employed 72, 73 . Computing polygenic risk scores requires individuallevel data in the validation cohort, implying that these methods are not strictly summary statistic based. Recent work has shown that the information in polygenic risk scores can be derived from summary-level data in the training and validation cohorts to estimate the heritability explained by SNPs and the number of causal variants 81 ; a limitation of this approach is that SNPs are assumed to be uncorrelated, which can be approximately achieved by LD-pruning but precludes analyses of dense marker panels. The heritability explained by SNPs can alternatively be estimated from the slope of LD score regression 82 , in which χ 2 statistics for each SNP are regressed against LD scores (sum of squared correlations with all SNPs), leveraging the fact that SNPs with higher LD scores are expected to contain more polygenic signal 83 . This approach explicitly allows for LD between SNPs and can distinguish between polygenicity and confounding, but makes strong assumptions about effect sizes of rare variants and thus currently only produces robust estimates for common variants.
Another recent method models LD while treating SNP effects as fixed rather than random (similar to ref. 81 ), enabling estimation of heritability explained by common SNPs in local regions as well as genome-wide 10 . Overall, summary statistic based methods provide a useful alternative to methods for estimating heritability explained by SNPs from individual-level data using restricted maximum likelihood (REML) and its extensions 84, 85 .
The increasing availability of functional annotation data (see above) can also be used to identify functional annotations that are enriched for polygenic signals of disease heritability. A recent study accomplished this using a Bayesian hierarchical model that splits the genome into blocks and incorporates both coarse-scale functional annotations at the level of blocks and fine-scale functional annotations at the level of SNPs 56 . This was the first study to quantify polygenic enrichments for cell-type-specific chromatin marks and DNase I hypersensitivity sites (DHS) across a broad set of complex traits and diseases. For example, polygenic signals for platelet volume and platelet count were enriched at DHS in CD34+ cells, which are on the cell lineage that lead to platelets, and polygenic signals for Crohn's disease were depleted at repressed chromatin in LCL, an immunerelated cell line. Functional enrichments can alternatively be estimated by stratified LD score regression 86 , which generalizes LD score regression 82 to regress χ 2 statistics for each SNP against LD scores with each functional category. Fine-mapping methods can also estimate functional enrichments, although these analyses are often restricted to disease-associated loci 44, 49, 58 . Notably, all of these summary statistic based methods have been applied to a large number of overlapping functional annotations, whereas methods that analyze individual-level genotypes have only been applied to a small number of non-overlapping functional annotations 87, 88 . In addition, stratified LD score regression is not limited by the single causal variant per block assumption of the Bayesian hierarchical model, increasing power in settings of highly polygenic traits 86 . Application of the method identified significant cell-type-specific enrichments for many highly polygenic traits, including enrichments for histone marks in brain for smoking behavior and educational attainment-even though the summary statistics analyzed contained only one and three genomewide significant loci, respectively. One limitation of the method is limited power for functional categories spanning a small percentage of the genome, motivating additional work in this area. As both summary statistic and functional annotation data sets grow larger and richer, identifying enriched functional annotations using summary statistic data will likely continue to be a fruitful endeavor.
Cross-trait analyses

Many complex traits and diseases have a shared genetic etiology, either via shared genetic variant(s)
with nonzero causal effect sizes (pleiotropy) or via a signed correlation between causal effect sizes (genetic correlation). Indeed, many instances of genetic variants with pleiotropic effects on multiple traits have been identified [89] [90] [91] [92] [93] [94] . A recent study applied a Bayesian framework to summary association statistics from pairs of traits to estimate, at each locus in the genome, the probability that an associated variant has pleiotropic effects on both traits 95 . Pleiotropic SNPs can also be utilized as instrumental variables in Mendelian randomization analyses from summary statistics [96] [97] [98] , with one such analysis showing that increased body mass index causally increases triglyceride levels 95 .
An alternate approach to assessing the genetic overlap between two traits is to estimate the correlation between causal effect sizes across the two traits. Genome-wide genetic correlations can be estimated from individual-level data using bivariate REML 99 . A recent study estimated genomewide genetic correlations from summary data using the information in polygenic risk scores, although this approach required LD-pruning the data which may lead to upwards bias 81 . Another recent study estimated genome-wide genetic correlations from summary data using cross-trait LD score regression 100 , which generalizes LD score regression to regress products of z-scores against LD scores for each SNP; this method produced estimates that were highly concordant with those from individual-level data 99 . Fitting the underlying MVN model using maximum likelihood instead of linear regression has produced promising results in applications to estimating cross-trait and cross-population genetic correlations, and may also prove useful in other settings 101 . Although genetic correlation analyses restricted to associated variants have also produced important findings 95 , the power of methods that leverage polygenic signals in genome-wide data is underscored by the discovery of significant genetic correlations involving traits with zero or few genome-wide significant loci, including a significant negative genetic correlation between smoking behavior and educational attainment 100 .
Conclusion
Recently developed methods have made it possible to leverage summary association statistics to perform a wide range of analyses, many of which previously required individual-level data. As the availability of summary association statistics continues to grow (Table 1) , summary statistics will continue to be broadly used in analyses involving single-variant association tests, gene-based association tests, fine-mapping, polygenic prediction and inferring polygenic architectures, and cross-trait analysis. The use of summary data will entail a slight loss of accuracy in some applications, such as imputation, where methods that analyze individual-level data can use haplotypes to model nonlinear structure, and polygenic prediction, where methods that analyze individual-level data can reduce noise by fitting all markers simultaneously; however, when summary statistics are available in larger sample size than individual-level data, the advantage of larger sample size will far outweigh those limitations. In addition, there are some settings where summary statistic based methods are the method of choice even when individual-level data is available, such as identifying functional annotations that are enriched for heritability, where methods that analyze individual-level data cannot currently handle a large number of overlapping annotations.
Despite considerable recent progress, there are some areas where further research on summary statistic based methods is needed. As population reference panels grow, more accurate modeling of rare and low-frequency variants will become possible, and it will be important to assess the limits of such efforts. It is also of interest to develop methods for inferring polygenic architectures from summary statistics that allow for different relationships between allele frequency and effect size.
Identifying functional annotations that are enriched for heritability is an application that is particularly likely to produce important biological insights, and here there is a need for new methods that are well-powered for functional categories spanning a small percentage of the genome. As the number of functional annotations continues to increase, the integration of such data poses computational and statistical challenges in disentangling the correct functional annotations among many correlated ones.
We conclude by emphasizing the importance of making summary association statistics publicly available. A 2012 editorial in the journal Nature Genetics asked its authors to publish or database summary association statistics for all SNPs analyzed 102 , broadly impacting the set of publicly available summary statistics in the years that followed ( Table 1 ). The public release of summary statistics is a useful compromise in situations where sample consent restrictions or privacy concerns preclude the release of individual-level data in a public repository. Although even the release of summary statistics can in principle lead to privacy concerns 103 , more recent work has shown that such privacy attacks have low power when the summary sample size exceeds the effective number of independent markers (currently estimated at 60,000 in typical GWAS data sets 104 ) , implying that privacy concerns should not preclude the public release of summary statistics from large studies [105] [106] [107] . Indeed, some recent studies have created web portals where summary data can be publicly accessed and visualized 60 . Finally, we note the potential benefits of publicly releasing summary statistics that include summary LD information (i.e. correlations) between each pair of proximal SNPs; however, the optimal approach to aggregating summary LD information across multiple cohorts in large-scale meta-analyses remains unclear, motivating future work in this area. 
Box 1: Conditional association and summary statistic imputation using LD reference data
Conditional association using LD reference data
We estimate the joint effects of all SNPs using least-squares as = *+ ) with = 0 1 *+ , where 0 1 is the residual variance in the joint analysis. In a standard GWAS, however, each SNP is marginally tested one at a time, which can be expressed in matrix form as 2 = *+ ) with 2 = 2 1 *+ , where is the (nearly constant) diagonal matrix of and 2 1 is the residual variance in the marginal analysis. It follows that: = *+ 2 and = 0 1 *+ . The mean and variance of the conditional distribution can be used to impute summary association statistics at untyped SNPs.
Summary statistic imputation using LD reference data
Box 2: Rare variant association tests using summary association statistics
Let X be an N x M matrix of genotypes, standardized to mean 0 and variance 1, and Y be an N x 1 matrix of standardized trait values, where M is the number of rare variants (e.g. in a given gene being tested for association) and N is the number of samples. An M x 1 vector of z-scores (estimated effect sizes divided by their s.e.) can be computed as = ) / , with multivariate normal null distribution ~0, , where is an in-sample LD matrix.
Burden tests
Burden tests assume that all rare variants in a candidate gene have the same direction of effect.
Burden tests may either assume that standardized effect sizes are the same for each rare variant 108 (i.e. per-allele effect sizes are proportional to 1/ F 1 − F , where p i is the allele frequency), or apply weights or thresholds based on allele frequency or functional information 109, 110 . If w is an M x 1 vector of weights for each rare variant (including zero weights for rare variants excluded by a threshold), the test statistic for a weighted burden test is NOPQ9R = ) with null distribution NOPQ9R~ (0, ) ). This test statistic can naturally be extended to meta-analysis of burden tests from multiple cohorts (via inverse-variance weighting), and can be extended to variable threshold tests and binary traits [36] [37] [38] .
Overdispersion tests
Overdispersion tests assume that rare variants in a candidate gene can impact a complex trait in either direction, and can be computed as weighted sums of squared single-variant test statistics 111, 112 . If W = diag(w 1 , …, w M ) is an M x M diagonal matrix of weights for each rare variant, the test statistic for a weighted overdispersion test is TU9PQF7V9P7FTR = ) with null distribution NOPQ9R~F F F 1 , where weights µ i for each χ 2 (1 d.o.f.) distribution χ i 2 are given by eigenvalues of the matrix +/1 +/1 . This test statistic can be extended to meta-analysis of overdispersion tests from multiple cohorts (via inverse-variance weighting), and can be extended to binary traits [36] [37] [38] .
Box 3: Polygenic risk prediction using summary vs. individual-level data
Suppose that polygenic risk prediction for a quantitative trait is conducted using a training cohort with N unrelated samples, using M unlinked markers with SNP-heritability 7 equal to h g 2 . We initially consider two polygenic risk prediction methods that assume infinitesimal (Gaussian) architectures: polygenic risk scores computed using marginal effects at all markers with no P-value thresholding (PRS all ), and fitting effect sizes of all markers simultaneously via Best Linear Unbiased Prediction (BLUP). We note that PRS all requires only summary statistics from the training cohort, whereas BLUP requires individual-level data. The prediction R 2 for each method are given by 80,113 These equations can naturally be extended to linked markers (using the effective number of unlinked markers 104 ) and case-control traits (using observed-scale SNP-heritability 114 ). The relative advantage of BLUP over PRS all is small when prediction R 2 is small in absolute terms, but grows larger when prediction R 2 is larger; this is illustrated in the figure below, which reports prediction R 2 at various training sample sizes based on M=60,000 unlinked markers and a SNP-heritability of h g 2 =0.5. These results generalize to non-infinitesimal extensions of polygenic risk scores 72, 74 and BLUP 78, 79 ; in the latter case, the noise reduction from fitting all markers simultaneously remains equal to 1-R 2 , corresponding to an increase in training sample size of 1/(1-R 2 ).
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